MK-3795

News alerts, weekly reports and conference planners

Company:

Merck (MSD)

Drug class:

HIF-2α antagonist

Related drugs:

‹

›

VHL mutation	Clear Cell Renal Cell Carcinoma	VHL mutation	Clear Cell Renal Cell Carcinoma	MK-3795 Sensitive: C2 – Inclusion Criteria MK-3795 Sensitive : C2	MK-3795 Sensitive: C2 – Inclusion Criteria MK-3795 Sensitive : C2
VHL mutation	Neuroendocrine Tumor	VHL mutation	Neuroendocrine Tumor	MK-3795 Sensitive: C3 – Early Trials MK-3795 Sensitive : C3	MK-3795 Sensitive: C3 – Early Trials MK-3795 Sensitive : C3

Associations
(2)